首页> 美国卫生研究院文献>Extreme Physiology Medicine >Fluid therapy in critical illness
【2h】

Fluid therapy in critical illness

机译:重大疾病中的液体疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Major surgery and critical illnesses such as sepsis and trauma all disturb normal physiological fluid handling. Intravenous fluid therapy for resuscitation and fluid maintenance is a central part of medical care during these conditions, yet the evidence base supporting practice in this area lacks answers to a number of important questions. Recent research developments include a refinement of our knowledge of the endothelial barrier structure and function and a focus on the potential harm that may be associated with intravenous fluid therapy. Here, we briefly describe the contemporary view of fluid physiology and how this may be disrupted by pathological processes. The important themes in critical illness fluid research are discussed, with a particular focus on two emerging ideas: firstly, that individualising fluid treatment to the patient, their underlying disease state and the phase of that illness may be key to improving clinical outcomes using fluid interventions and, secondly, that fluids should be considered to be drugs, with specific indications and contraindications, dose ranges and potential toxicities.
机译:重大手术和严重疾病(如败血症和创伤)都会干扰正常的生理液处理。在这些情况下,用于复苏和维持体液的静脉输液疗法是医疗保健的核心部分,但是该领域的证据支持实践缺乏对许多重要问题的解答。最近的研究进展包括对我们对内皮屏障结构和功能的认识的完善,以及对可能与静脉输液治疗有关的潜在危害的关注。在这里,我们简要描述了流体生理学的当代观点以及病理过程如何破坏这种观点。讨论了重大疾病液体研究中的重要主题,特别着重于两个新出现的想法:首先,针对患者个性化液体治疗,患者的潜在疾病状态和疾病阶段可能是使用液体干预改善临床结果的关键其次,应将液体视为具有特定适应症和禁忌症,剂量范围和潜在毒性的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号